Company research
CONMED Corp
CIK 816956Updated Sep 24, 2026
SecurityCNMD · NYSE · equity
CNMD price & chart
Loading TradingView…
NYSE:CNMD on TradingView ↗About the company
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
11-K filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,325,749,000Source | 2,306,247,000Source | 2,300,021,000Source | 2,297,592,000Source |
| Property, Plant and Equipment, NetUSD | 113,331,000Source | 115,793,000Source | 120,722,000Source | 115,611,000Source |
| GoodwillUSD | 807,011,000Source | 805,358,000Source | 806,844,000Source | 815,429,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 582,051,000Source | 617,663,000Source | 649,484,000Source | 681,799,000Source |
| Current assets: | ||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 247,830,000Source | 237,733,000Source | 242,279,000Source | 191,345,000Source |
| Inventory, NetUSD | 355,544,000Source | 346,719,000Source | 318,324,000Source | 332,320,000Source |
| Assets, CurrentUSD | 672,860,000Source | 640,007,000Source | 615,649,000Source | 581,226,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 28,669,000Source | 31,096,000Source | 30,750,000Source | 28,619,000Source |
| Operating Lease, Right-of-Use AssetUSD | 48,988,000Source | 39,839,000Source | 16,606,000Source | 17,710,000Source |
| Other Assets, NoncurrentUSD | 137,187,000Source | 116,357,000Source | 96,111,000Source | 93,877,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,292,652,000Source | 1,343,566,000Source | 1,465,799,000Source | 1,552,047,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 313,000Source | 313,000Source | 313,000Source | 313,000Source |
| Additional Paid in CapitalUSD | 503,200,000Source | 476,575,000Source | 446,535,000Source | 413,235,000Source |
| Retained Earnings (Accumulated Deficit)USD | 588,766,000Source | 560,277,000Source | 452,531,000Source | 412,631,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -46,295,000Source | -58,857,000Source | -50,170,000Source | -57,858,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,033,097,000Source | 962,681,000Source | 834,222,000Source | 745,545,000Source |
| Liabilities and EquityUSD | 2,325,749,000Source | 2,306,247,000Source | 2,300,021,000Source | 2,297,592,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 315,041,000Source | 278,130,000Source | 310,729,000Source | 296,552,000Source |
| Operating Lease, Liability, CurrentUSD | 8,612,000Source | 8,093,000Source | 7,509,000Source | 6,919,000Source |
| Accounts Payable, CurrentUSD | 93,648,000Source | 102,248,000Source | 88,224,000Source | 73,393,000Source |
| Operating Lease, Liability, NoncurrentUSD | 43,932,000Source | 33,282,000Source | 9,897,000Source | 11,759,000Source |
| Deferred Income Tax Liabilities, NetUSD | 79,530,000Source | 74,076,000Source | 60,902,000Source | 66,725,000Source |
| Other Liabilities, NoncurrentUSD | 63,851,000Source | 86,294,000Source | 121,028,000Source | 203,694,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 66,221,000Source | 63,007,000Source | 49,691,000Source | 57,075,000Source |
| Dividends PayableUSD | 0Source | 6,180,000Source | 6,153,000Source | 6,098,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 28,323,000Source | 25,558,000Source | 24,257,000Source | 21,729,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 2,361,000Source | 1,619,000Source | 47,068,000Source | 5,203,000Source |
| Increase (Decrease) in InventoriesUSD | 6,733,000Source | 31,633,000Source | -14,071,000Source | 78,564,000Source |
| Increase (Decrease) in Accounts PayableUSD | -9,749,000Source | 14,713,000Source | 14,849,000Source | 13,302,000Source |
| Deferred Income Tax Expense (Benefit)USD | 3,523,000Source | 12,202,000Source | 700,000Source | -6,042,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 170,689,000Source | 166,968,000Source | 125,348,000Source | 33,365,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -20,956,000Source | -13,084,000Source | -20,032,000Source | -249,529,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | 1,150,000Source | 0Source | 1,000,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 19,806,000Source | 13,084,000Source | 19,032,000Source | 21,785,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -135,820,000Source | -151,000,000Source | -110,432,000Source | 225,000,000Source |
| Payments of Ordinary Dividends, Common StockUSD | 24,746,000Source | 24,651,000Source | 24,502,000Source | 23,960,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 170,000Source | 2,833,000Source | 15,937,000Source | 8,475,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 16,358,000Source | 163,000Source | -4,646,000Source | 8,095,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 40,817,000Source | 24,459,000Source | 24,296,000Source | 28,942,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 25,417,000Source | 32,654,000Source | 33,687,000Source | 26,081,000Source |
| Income Taxes Paid, NetUSD | 20,978,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,445,000Source | -2,721,000Source | 470,000Source | -741,000Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | 5,646,000Source | 5,700,000Source | 6,058,000Source | 4,910,000Source |
| Amortization of Intangible AssetsUSD | 35,200,000Source | 34,700,000Source | 35,200,000Source | 33,700,000Source |
| Capitalized Computer Software, AmortizationUSD | 1,200,000Source | 1,400,000Source | 1,700,000Source | 2,100,000Source |
| DepreciationUSD | 17,143,000Source | 16,605,000Source | 16,200,000Source | 16,055,000Source |
| Dividends PayableUSD | 0Source | 6,180,000Source | 6,153,000Source | 6,098,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -313,000Source | -3,043,000Source | -1,305,000Source | -1,950,000Source |
| General and Administrative ExpenseUSD | 131,963,000Source | 117,463,000Source | — | — |
| GoodwillUSD | 807,011,000Source | 805,358,000Source | 806,844,000Source | 815,429,000Source |
| Income Tax Expense (Benefit)USD | 24,062,000Source | 30,606,000Source | 16,369,000Source | 9,720,000Source |
| Net Income (Loss) Attributable to ParentUSD | 47,055,000Source | 132,423,000Source | 64,459,000Source | -80,582,000Source |
| Operating ExpensesUSD | 647,853,000Source | 532,706,000Source | 555,642,000Source | 501,191,000Source |
| Operating Lease, ExpenseUSD | 11,001,000Source | 8,933,000Source | — | 7,685,000Source |
| Operating Lease, Impairment LossUSD | 0Source | 606,000Source | — | — |
| Payments for Repurchase of WarrantsUSD | — | 0Source | 0Source | 69,534,000Source |
| Proceeds from Stock Options ExercisedUSD | 200,000Source | 3,400,000Source | 16,200,000Source | 8,900,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,374,724,000Source | 1,307,015,000Source | 1,244,744,000Source | 1,045,472,000Source |
| Cost of RevenueUSD | 624,249,000Source | 573,983,000Source | 568,499,000Source | 474,227,000Source |
| Selling, General and Administrative ExpenseUSD | 591,969,000Source | 478,280,000Source | 503,040,000Source | 454,039,000Source |
| Operating Income (Loss)USD | 102,622,000Source | 200,326,000Source | 120,603,000Source | 70,054,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 71,117,000Source | 163,029,000Source | 80,828,000Source | -70,862,000Source |
| Income Tax Expense (Benefit)USD | 24,062,000Source | 30,606,000Source | 16,369,000Source | 9,720,000Source |
| Net Income (Loss) Attributable to ParentUSD | 47,055,000Source | 132,423,000Source | 64,459,000Source | -80,582,000Source |
| Earnings Per Share, BasicUSD per share | 1.52Source | 4.29Source | 2.1Source | -2.68Source |
| Earnings Per Share, DilutedUSD per share | 1.51Source | 4.25Source | 2.04Source | -2.68Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 31,036,000Source | 30,846,000Source | 30,668,000Source | 30,040,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 31,149,000Source | 31,150,000Source | 31,548,000Source | 30,040,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 35,200,000Source | 34,700,000Source | 35,200,000Source | 33,700,000Source |
| Capitalized Computer Software, AmortizationUSD | 1,200,000Source | 1,400,000Source | 1,700,000Source | 2,100,000Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0.6Source | 0.8Source | 0.8Source | 0.8Source |
| Current Income Tax Expense (Benefit)USD | 20,539,000Source | 18,404,000Source | 15,669,000Source | 15,762,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -313,000Source | -3,043,000Source | -1,305,000Source | -1,950,000Source |
| General and Administrative ExpenseUSD | 131,963,000Source | 117,463,000Source | — | — |
| Gross ProfitUSD | 750,475,000Source | 733,032,000Source | 676,245,000Source | 571,245,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 34,063,000Source | 124,401,000Source | 51,568,000Source | -96,114,000Source |
| Interest ExpenseUSD | 31,087,000Source | 37,297,000Source | 39,775,000Source | 28,905,000Source |
| Operating ExpensesUSD | 647,853,000Source | 532,706,000Source | 555,642,000Source | 501,191,000Source |
| Operating Lease, ExpenseUSD | 11,001,000Source | 8,933,000Source | — | 7,685,000Source |
| Other ExpensesUSD | 418,000Source | — | — | — |
| Research and Development ExpenseUSD | 55,884,000Source | 54,426,000Source | 52,602,000Source | 47,152,000Source |
Filing attachments
ea029501601ex99-1.htm · 8-K · 2026-06-17
EX-99.1 3 ea029501601ex99-1.htm PRESS RELEASE ISSUED BY CONMED CORPORATION DATED JUNE 17, 2026 Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Dalton Henry Investor Relations Analyst IR@conmed.com CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer Largo, Fla. - June 17, 2026 - CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”), effective July 15, 2026. Mr. Gallagher succeeds Todd G…
Read attachment ↗ex99-1.htm · 8-K · 2026-01-12
EX-99.1 2 ex99-1.htm EX-99.1 J.P. Morgan 44 th Annual Healthcare Conference Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer January 12 th, 2026 Forward - Looking Information This presentation may contain forward - looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the …
Read attachment ↗ea026855401ex99-1_conmed.htm · 8-K · 2025-12-05
EX-99.1 2 ea026855401ex99-1_conmed.htm PRESS RELEASE, DATED DECEMBER 5, 2025, ISSUED BY CONMED CORPORATION Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer ToddGarner@conmed.com CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines Concludes Distribution Agreement with Gore ® for VIABIL ® in the United States and Canada, Effective January 1, 2026 Announces Intent to Exit Remaining Products in its Gastroente…
Read attachment ↗ex99-1.htm · 8-K · 2025-09-09
EX-99.1 2 ex99-1.htm EX-99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer ToddGarner@conmed.com CONMED Corporation Adds Kim Kelderman to its Board of Directors Largo, Fla. - September 9, 2025 - CONMED Corporation (NYSE: CNMD) today announced that Kim Kelderman will be joining its Board of Directors effective September 8, 2025. “My fellow directors and I are delighted to welcome Kim to the board,” said LaVerne Council, Chair of CONMED’s Board of …
Read attachment ↗ea024818601ex99-1_conmed.htm · 8-K · 2025-07-07
EX-99.1 2 ea024818601ex99-1_conmed.htm PRESS RELEASE, DATED JULY 7, 2025, ISSUED BY CONMED CORPORATION Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer ToddGarner@conmed.com Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Officer of Merit Medical Systems, Inc. Largo, Fla. - July 7, 2025 - CONMED Corporation (NYSE: CNMD) today announced that Martha Aronson will be stepping…
Read attachment ↗ex99-1.htm · 8-K · 2025-04-30
EX-99.1 2 ex99-1.htm EX-99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2025 Financial Results Largo, Florida, April 30, 2025 - CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant curr…
Read attachment ↗